Rapid Micro Biosystems, Inc. Class A ( (RPID) ) has released its Q1 earnings. Here is a breakdown of the information Rapid Micro Biosystems, Inc. Class A presented to its investors.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rapid Micro Biosystems, Inc., headquartered in Lexington, Massachusetts, is a life sciences technology company specializing in automation solutions for microbial quality control in pharmaceutical manufacturing. The company’s flagship product, the Growth Direct system, enhances efficiency and accuracy in quality control processes.
In its first quarter of 2025, Rapid Micro Biosystems reported a 28% increase in total revenue, reaching $7.2 million, compared to the same period in 2024. This growth was driven by record service revenues and a significant improvement in gross margins.
Key financial highlights include a 64% increase in service revenue and a 10% increase in product revenue. The company also reported a notable improvement in gross margin, which rose to 6% from a negative 27% in the previous year. Operating expenses decreased by 5%, contributing to a reduced net loss of $11.3 million, down from $13.3 million in the first quarter of 2024.
Strategically, Rapid Micro Biosystems announced a global Distribution and Collaboration Agreement with MilliporeSigma, aiming to accelerate system placements and innovate new products. The company reaffirmed its full-year revenue guidance of at least $32 million.
Looking ahead, Rapid Micro Biosystems remains focused on enhancing product cost efficiency and expanding its market presence through strategic partnerships, positioning itself for continued growth and innovation in the life sciences sector.